
    
      All patients will receive sitravatinib 120 mg orally once daily in combination with
      tislelizumab 200 mg IV once every 3 weeks until occurrence of PD, unacceptable toxicity,
      death, withdrawal of consent, or study termination by sponsor.

      There will be 9 cohorts in the study. Approximately 20 patients will be enrolled into each
      cohort. The patients will be enrolled according to their tumor type and prior anti-programmed
      cell death protein-1 (PD-1)/PD-L1 antibody treatment.

        -  Cohort A: Anti-PD-1/PD-L1 antibody refractory/resistant metastatic, non-squamous NSCLC

        -  Cohort B: Anti-PD-1/PD-L1 antibody naïve metastatic, non-squamous NSCLC

        -  Cohort C: Anti-PD-1/PD-L1 antibody refractory/resistant metastatic or advanced RCC

        -  Cohort D (China-only): Metastatic or advanced RCC without prior systemic therapy

        -  Cohort E: Anti-PD-1/PD-L1 antibody naïve recurrent and platinum resistant epithelial OC

        -  Cohort F: Anti-PD-1/PD-L1 antibody treated metastatic, squamous NSCLC • Cohort G:
           Anti-PD-1/PD-L1 antibody refractory/resistant unresectable or metastatic melanoma

        -  Cohort H: PD-L1 positive, aive, advanced or metastatic, non-squamous NSCLC

        -  Cohort I: PD-L1 positive,naive, advanced or metastatic, squamous NSCLC
    
  